# BrainChild Bio

Source: https://onco.cc/companies/brainchild-bio/  
OnCo record `brainchild-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BrainChild Bio develops CAR-T cell therapies for brain tumours, starting with children. Its lead treatment, for diffuse intrinsic pontine glioma, a brainstem tumour of childhood, entered a phase 2 trial in 2026 intended to support an application for approval.

## Summary

BrainChild Bio, with offices in Seattle and Cambridge, Massachusetts, is a clinical-stage company developing CAR-T therapies for tumours of the central nervous system, built on technology developed at Seattle Children's and exclusively licensed to the company in December 2023. On 8 September 2026 it announced a USD 116 million Series A led by an undisclosed private family fund and foundation, with Seattle Children's, its initial investor, and WRF Capital.

Most of the money goes to ILLUMINATE (NCT07680439), a pivotal phase 2 trial of BCB-276, an autologous B7-H3-targeted CAR-T for diffuse intrinsic pontine glioma (DIPG), designed to support a future Biologics License Application to the FDA. The financing also supports BCB-214, a triple-targeting CAR-T being advanced to initial clinical testing in glioblastoma, and further paediatric and adult brain tumour programmes, including brain metastases.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Seattle, WA
- Type: cell-therapy
- Website: https://www.brainchildbio.com/

## Notes

- Founding year not stated in the release; the licence from Seattle Children's dates from December 2023. Earlier support from Seattle Children's is described only as its initial investment, with no amount.

## Sources

- Official website: https://www.brainchildbio.com/
- Series A press release, September 2026: https://www.biospace.com/press-releases/brainchild-bio-closes-116-million-series-a-financing
- ClinicalTrials.gov: NCT07680439: https://clinicaltrials.gov/study/NCT07680439

## Connected records

- cancers: [Diffuse midline glioma, H3 K27-altered (including DIPG)](https://onco.cc/cancers/dipg-dmg/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)](https://onco.cc/technologies/glioma-car-t/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/)
- trials: [Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).](https://onco.cc/trials/nct07680439/)

---
JSON: https://onco.cc/api/v1/entities/brainchild-bio.json